| 摘要 |
The invention relates to novel crystalline forms of 3-[ [3, 5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid, said crystalline forms being characterised by a powder X-ray diffraction pattern having major peaks at either 2R = 16.1±0.2, 20.1±0.2, 20.7±0.2, and 24.2+0.2; or 2R = 9.0±0.2, 14.7±0.2, 19.6±0.2, 21.6±0.2, and 24.3+0.2.
|
